<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d49" origId="Adalimumab"><sentence id="DrugDDI.d49.s0" origId="s0" text="Methotrexate HUMIRA has been studied in rheumatoid arthritis patients taking concomitant MTX."><entity id="DrugDDI.d49.s0.e0" origId="s0.p0" charOffset="0-12" type="drug" text="Methotrexate"/><entity id="DrugDDI.d49.s0.e1" origId="s0.p6" charOffset="89-92" type="drug" text="MTX"/><pair id="DrugDDI.d49.s0.p0" e1="DrugDDI.d49.s0.e0" e2="DrugDDI.d49.s0.e1" interaction="false"/></sentence><sentence id="DrugDDI.d49.s1" origId="s1" text="The data do not suggest the need for dose adjustment of either HUMIRA or MTX."><entity id="DrugDDI.d49.s1.e0" origId="s1.p15" charOffset="63-69" type="drug" text="HUMIRA"/><entity id="DrugDDI.d49.s1.e1" origId="s1.p17" charOffset="73-76" type="drug" text="MTX"/><pair id="DrugDDI.d49.s1.p0" e1="DrugDDI.d49.s1.e0" e2="DrugDDI.d49.s1.e1" interaction="false"/></sentence><sentence id="DrugDDI.d49.s2" origId="s2" text="Anakinra Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone."><entity id="DrugDDI.d49.s2.e0" origId="s2.p18" charOffset="0-8" type="drug" text="Anakinra"/><entity id="DrugDDI.d49.s2.e1" origId="s2.p19" charOffset="38-46" type="drug" text="anakinra"/><entity id="DrugDDI.d49.s2.e2" origId="s2.p21" charOffset="51-76" type="drug" text="interleukin-1 antagonist"/><entity id="DrugDDI.d49.s2.e3" origId="s2.p35" charOffset="251-268" type="drug" text="medicinal product"/><pair id="DrugDDI.d49.s2.p0" e1="DrugDDI.d49.s2.e0" e2="DrugDDI.d49.s2.e1" interaction="false"/><pair id="DrugDDI.d49.s2.p1" e1="DrugDDI.d49.s2.e0" e2="DrugDDI.d49.s2.e2" interaction="false"/><pair id="DrugDDI.d49.s2.p2" e1="DrugDDI.d49.s2.e0" e2="DrugDDI.d49.s2.e3" interaction="false"/><pair id="DrugDDI.d49.s2.p3" e1="DrugDDI.d49.s2.e1" e2="DrugDDI.d49.s2.e2" interaction="false"/><pair id="DrugDDI.d49.s2.p4" e1="DrugDDI.d49.s2.e1" e2="DrugDDI.d49.s2.e3" interaction="false"/><pair id="DrugDDI.d49.s2.p5" e1="DrugDDI.d49.s2.e2" e2="DrugDDI.d49.s2.e3" interaction="false"/></sentence><sentence id="DrugDDI.d49.s3" origId="s3" text="The safety and efficacy of anakinra used in combination with HUMIRA has not been studied."><entity id="DrugDDI.d49.s3.e0" origId="s3.p39" charOffset="27-35" type="drug" text="anakinra"/><entity id="DrugDDI.d49.s3.e1" origId="s3.p42" charOffset="61-67" type="drug" text="HUMIRA"/><pair id="DrugDDI.d49.s3.p0" e1="DrugDDI.d49.s3.e0" e2="DrugDDI.d49.s3.e1" interaction="false"/></sentence><sentence id="DrugDDI.d49.s4" origId="s4" text="Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities."><entity id="DrugDDI.d49.s4.e0" origId="s4.p49" charOffset="30-38" type="drug" text="anakinra"/><entity id="DrugDDI.d49.s4.e1" origId="s4.p52" charOffset="81-87" type="drug" text="HUMIRA"/><pair id="DrugDDI.d49.s4.p0" e1="DrugDDI.d49.s4.e0" e2="DrugDDI.d49.s4.e1" interaction="true"/></sentence></document>